ClinicalTrials.gg
Not yet recruitingNCT06648109Updated Oct 18, 2024

Effects of Sleep Body Temperature on Body Composition

An interventional study of Electric Blanket in Blood Pressure Check (Hypertension Screening), Heart Rate and Aldosterone Disorder, sponsored by Jinan University Guangzhou. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Jinan University Guangzhou · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
263rd of 308
40 · median 253
Started
2024
with 29 others
No phase
146 of 410
56 open now
Primary completion
2025-01
later than 15 of 147 live
Registered
305th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 263rd largest by planned enrollment of the 308 interventional ones that give a count, is one of 30 that started in 2024, is one of 146 with no phase, reaches primary completion later than 15 of the 147 other live ones, and was the 305th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This will be a crossover controlled trial designed to recruit 40 participants, who will be divided into two groups of 20 subjects each. The participants will be randomly assigned to either Group A or Group B. Group A will receive the sleep electric blanket intervention for a period of 7 days, while Group B will serve as the control group without any additional intervention. After the intervention period, there will be a washout period of 7 days to ensure that any effects of the intervention have subsided before the crossover.

Following the washout period, the groups will switch roles: Group B will then receive the sleep electric blanket intervention, and Group A will become the control group. This second phase will also last for 7 days, preceded and followed by the same assessment procedures as the initial phase. This design will allow for a comparison of the intervention's effects against a control period within the same group of participants, enhancing the study's internal validity.

03

Conditions studied

  • Blood Pressure Check (Hypertension Screening)
  • Heart Rate
  • Aldosterone Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18-30 years, inclusive of both male and female genders.

Exclusion criteria

Exclusion Criteria:

  • Individuals suffering from serious diseases such as heart, liver, kidney, brain, hematopoietic, immune, thyroid, malignant tumors, etc.;
  • Those with familial hereditary hypertension (both parents are hypertensive) or those diagnosed with hypertension;
  • Individuals with cognitive or mental impairments that prevent the completion of the questionnaire;
  • Persons with physical disabilities that hinder normal walking;
  • Persons who have experienced a weight change of >3.0 kg within 1 month or >10 kg within 6 months prior to screening (as per the study in Nutrients. 2020 Oct 21;12(10):3221);
  • Individuals required to take antibiotics from one week before the trial starts until its conclusion;
  • Those with habitual diarrhea or who have experienced diarrhea from one week before the trial starts until its end;
  • Subjects who have participated in other ambient temperature-related trials within the last 6 months;
  • Individuals with extreme sleep schedules (i.e., not falling asleep between 21:00 and 2:00 a.m. the following morning, or waking up before 5:00 a.m.);
  • Those with sleep latency (the time it takes to fall asleep after going to bed) greater than one hour;
  • Pittsburgh Sleep Quality Index (PSQI) scores greater than 16;
  • Participants who do not sign the form or are deemed unsuitable by the investigator for any other reason.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Mild-heat group

    Participants will be randomized into groups A and B. When the subject's group cohort undergoes the intervention phase (as opposed to the control phase), they will receive a 7-day, 8-hour intervention with an electric blanket set at +5±1°C above room temperature.

    Device: Electric Blanket

  • No intervention
    Non-mild-heat group

    Participants will be randomized into groups A and B. There will be no additional sleep temperature intervention while the group is in the control period.

Interventions

  • DeviceElectric Blanket

    Participants were randomized to groups A and B. When the subject\'s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Including systolic blood pressure (SBP) and diastolic blood pressure (DBP), Includes office blood pressure, home blood pressure and ambulatory blood pressure.

    Time frame: 1month

07

Study locations

1 site
  • Jinan University Guangzhou
    Guangzhou, Select a State 510632, China
08

References and documents

Individual participant data

Plan to share: Yes — The experiment will be made public upon completion with the publication of the related paper, sharing: contact the researcher for a copy.

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Jan 2025, 3 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 3 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 18, 2024
StartEst.
Oct 20, 2024
Primary completionEst.
Jan 30, 2025
CompletionEst.
Jan 30, 2025
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06648109
Lead sponsor
Jinan University Guangzhou
Responsible party
Fangfang Zeng (Associate Professor, Jinan University Guangzhou) — Principal investigator
First posted
Oct 18, 2024
Start date
Oct 20, 2024 (estimated)
Primary completion
Jan 30, 2025 (estimated)
Completion
Jan 30, 2025 (estimated)
Last update
Oct 18, 2024

Study contacts

Fangfang Zeng
Contact
zengffjnu@126.com
+86 13822285635
Jiamin Qiu
Contact
adniminday@163.com
+86 178196663352

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion